Sirolimus rapamycin results: what the research actually shows

Last updated 2026-07-27

What does the research actually show about rapamycin and lifespan?

The honest summary is this: rapamycin is one of the best-replicated lifespan-extension compounds ever tested in mammals, and it has never been tested for lifespan extension in a completed human trial. Both halves of that sentence matter equally. The mouse data comes mainly from the National Institute on Aging's Interventions Testing Program (ITP), a multi-site effort launched in 2004 that tests candidate compounds in genetically diverse mice across three labs (Jackson Laboratory, University of Michigan, and University of Texas Health Science Center) to reduce the chance of a fluke result ^[1]. Rapamycin was the first compound the ITP found to extend lifespan in both sexes, and it has now been retested at multiple doses and starting ages with consistent, dose-dependent effects ^[1]. In the original 2009 Nature paper, rapamycin encapsulated in food was started at 600 days of age (roughly equivalent to a 60-year-old human) and still extended median lifespan by 9% in males and 13% in females ^[2]. That result got attention specifically because the intervention started late in life, in mice that were already old, and still worked. Later ITP cohorts using higher doses starting earlier in life pushed the lifespan extension figure as high as 23% to 26% in females at the highest doses tested ^[3]. No human study has replicated any part of this. Sirolimus is FDA-approved as an immunosuppressant for organ transplant rejection, and separately approved under other brand names for specific rare conditions (Fyarro for a form of sarcoma, Hyftor topical for tuberous sclerosis skin lesions), never for aging or lifespan extension ^{[4] [5]}. Every use of rapamycin for longevity purposes is off-label, meaning a doctor is prescribing an approved drug for an unapproved purpose, which is legal but unsupported by the trials that got the drug approved in the first place.

What's the strongest animal evidence for rapamycin's longevity effect?

The ITP mouse data is the strongest evidence, and it is genuinely strong by the standards of aging research, which is a field full of compounds that look good in one lab and fail everywhere else. Three things make the ITP data unusually credible. First, it's multi-site: the same compound, same protocol, tested independently at three institutions, which catches lab-specific artifacts that plague a lot of single-lab aging studies. Second, it uses genetically heterogeneous mice (a four-way cross, UM-HET3) rather than inbred strains, so the result isn't just an artifact of one strain's quirks. Third, it's been replicated across multiple cohorts over more than a decade, with consistent direction of effect even as researchers varied dose and start age ^{[1] [3]}. Beyond the ITP, other groups have shown rapamycin extends lifespan and improves markers of healthspan (heart function, immune function, cognitive measures) in various mouse and rat models, and dog studies are underway. The Dog Aging Project's "Test of Rapamycin in Aging Dogs" (TRIAD) trial is a randomized, placebo-controlled, dose-ranging study in middle-aged pet dogs, chosen partly because dogs share our environment and get many of the same age-related diseases, and results on healthspan and cardiac function have started to emerge, though it is not a completed lifespan readout yet ^[6]. What hasn't been shown, in any species, is that the low, intermittent, pulsed weekly doses commonly used off-label in humans (often 5-6 mg once a week, versus daily dosing in transplant patients) produce anything like the mouse lifespan effect. The intermittent dosing strategy popular in longevity clinics is itself extrapolated from a hypothesis about avoiding chronic mTOR suppression, not from a dosing regimen that was tested for lifespan extension in the ITP studies, which used continuous dietary exposure ^{[2] [3]}.

Has rapamycin been tested for lifespan extension in humans?

No completed trial has tested rapamycin for lifespan extension, or even long-term healthspan extension, in humans. This is the single most important fact in this entire topic and it is worth restating plainly: there is no finished human trial showing rapamycin extends life or meaningfully slows aging in people. What does exist is a small set of short-duration studies looking at surrogate markers, not lifespan itself. A widely cited 2014 study in Science Translational Medicine gave elderly volunteers (age 65+) a mTOR inhibitor (RAD001, an analog closely related to rapamycin) for six weeks and found improved response to influenza vaccination, a proxy for immune function, not a lifespan outcome ^[7]. A separate small trial (PEARL, led by researchers including Matt Kaeberlein's group in collaboration with AgelessRx) looked at low-dose intermittent rapamycin in healthy adults over about 48 weeks and reported some improvements in reported quality of life measures and no serious safety signals at low doses, but it was small, not powered for hard outcomes, and did not measure lifespan or disease incidence ^[8]. There is currently no ongoing Phase 3 human trial with a lifespan or major clinical endpoint for off-label longevity dosing that has reported results. Anyone telling you "rapamycin is proven to extend human lifespan" is overstating what the literature contains. The honest claim is: strong mouse evidence, a documented biological mechanism, and a handful of small, short human studies on side biomarkers. That's a reasonable basis for cautious, medically supervised off-label use in an informed patient, not a basis for confident life-extension claims.

How does rapamycin work at the cellular level (the mTOR mechanism)?

Rapamycin blocks mTOR (mechanistic target of rapamycin), a protein complex that acts as a master regulator of cell growth, metabolism, and nutrient sensing. mTOR exists in two complexes, mTORC1 and mTORC2, and rapamycin primarily inhibits mTORC1 at the doses typically used. The longevity hypothesis, built from decades of yeast, worm, fly, and mouse genetics, goes like this: when mTORC1 activity is reduced, cells shift away from growth-and-build mode and toward maintenance-and-recycling mode. This upregulates autophagy (the cell's internal cleanup process for damaged proteins and organelles), which many researchers believe underlies much of the lifespan extension seen across species when nutrient-sensing pathways are dialed down (the same broad pathway is implicated in the lifespan effects of caloric restriction). This mechanism is genuinely well established in basic biology; it's not a fringe theory. The uncertainty isn't about whether rapamycin inhibits mTOR (it does, reliably) or whether reduced mTOR signaling extends lifespan in short-lived model organisms (it does, repeatedly). The uncertainty is whether the same dial, turned the same way, produces the same benefit in a long-lived, complex mammal like a human, at a dose that doesn't cause unacceptable side effects. That's an empirical question nobody has answered yet with a real trial.

What are the real risks and side effects of off-label rapamycin use?

The side effect profile comes almost entirely from decades of use in transplant patients at continuous, much higher doses than longevity protocols use, so it needs translation, not direct copying, but it tells you what to watch for. Immunosuppression is the headline risk. Rapamycin's FDA label for transplant use carries warnings about increased susceptibility to infection and a risk of malignancy from chronic immune suppression . At transplant doses this is a serious, well-documented risk. At the low, intermittent doses used off-label (often once weekly rather than daily), the immunosuppressive effect is presumed to be much smaller, and this is part of the argument for intermittent dosing, but there is no long-term human safety data proving that assumption holds over years of use. Mouth ulcers (stomatitis) are one of the most commonly reported side effects even at low, intermittent off-label doses, showing up in a meaningful minority of users in clinic-reported experience and in the transplant literature as a known class effect . They're usually manageable and dose-related but are the single most common reason people cited for dose adjustment. Metabolic effects are the other real concern. Rapamycin and mTOR inhibitors as a class are associated with dyslipidemia (elevated cholesterol and triglycerides) and, in some patients, new-onset hyperglycemia or worsened insulin resistance, effects documented in the transplant population and flagged in FDA labeling . This is somewhat paradoxical given the longevity framing, since some studies show rapamycin can improve certain metabolic and insulin-sensitivity markers in mice while others show it can impair glucose tolerance, and the net human effect at low intermittent doses isn't well characterized. This is exactly the kind of thing that needs monitoring; routine labs before and during use are how a prescriber catches a bad trend before it becomes a problem. Other reported effects include delayed wound healing, elevated blood pressure in some patients, and, rarely, lung inflammation (pneumonitis) at higher doses, again drawn mostly from transplant-dose experience . Anyone considering off-label use should read the full picture of long-term side effects and understand their own contraindications before starting, particularly with pre-existing lipid disorders, active infections, poor wound healing, or a history of certain cancers.

Is rapamycin the same thing as sirolimus?

Yes. Sirolimus is the generic drug name; rapamycin is the original name given to the compound when it was first isolated from Streptomyces hygroscopicus, a bacterium found in soil on Easter Island (Rapa Nui), which is where the name comes from . In the scientific literature and in longevity circles, the words are used interchangeably to refer to the same molecule. Brand-name and modified versions add confusion. Rapamune is the original FDA-approved brand of oral sirolimus for transplant rejection . Fyarro is an injectable nanoparticle formulation of sirolimus approved for a rare soft-tissue sarcoma ^[4]. Hyftor is a topical sirolimus gel approved for facial skin lesions in tuberous sclerosis ^[5]. Everolimus (brand names Afinitor, Zortress) is a related but chemically distinct rapamycin analog (a "rapalog") used in transplant medicine and oncology; it's not identical to sirolimus, though it shares the same mTOR mechanism. When you see "rapamycin" discussed in an aging study and "sirolimus" on a prescription label, they're the same active molecule.

What dose and schedule do longevity users actually take, and is it studied?

Most off-label longevity protocols use intermittent, low-dose sirolimus, commonly in the range of 3 to 10 mg taken once weekly, rather than the daily continuous dosing used in transplant medicine (which is typically dosed to a target blood trough level and taken every day) ^[8] . The rationale for intermittent dosing is a hypothesis, drawn from animal pharmacokinetic work, that a weekly pulse can inhibit mTORC1 (thought to drive most of the longevity benefit) while giving mTORC2 time to recover between doses (chronic mTORC2 inhibition is linked to some of the metabolic side effects). That hypothesis has not been validated by a completed human outcomes trial. The small PEARL study used a range of doses (5 mg, 6 mg, and 10 mg weekly) and found the regimens to be reasonably well tolerated over roughly a year, with mouth ulcers being the main dose-limiting side effect reported, but again, it measured tolerability and some quality-of-life and biomarker measures, not lifespan or hard disease outcomes ^[8]. Because there's no validated standard protocol, dosing in practice varies a lot between prescribers, and it should be individualized based on body weight, kidney and liver function, concurrent medications (rapamycin has significant drug interactions, including with CYP3A4 substrates and grapefruit juice, which can raise blood levels substantially) , and monitoring through blood work. A dosage calculator can help estimate a starting range based on published protocols, but it's a starting point for a conversation with a prescriber, not a substitute for one, and dose adjustments should be guided by lab monitoring, not by a fixed schedule alone.

Do any human studies show anti-aging biomarker changes from rapamycin?

A few small studies show changes in biomarkers plausibly linked to aging, but nothing that constitutes proof of slowed aging or extended lifespan in humans. The 2014 Mannick et al. trial in elderly adults found that a mTOR inhibitor improved antibody response to flu vaccine, interpreted as evidence of restored immune function in older adults, a biologically interesting and clinically relevant signal in its own right, but it's an immune-response endpoint measured over weeks, not an aging or lifespan endpoint ^[7]. A related follow-on study by the same group found reduced rates of reported infections in elderly subjects taking a low-dose mTOR inhibitor combination over a winter season ^[7]. The PEARL trial, run over about 48 weeks in adults 50 to 85, reported some improvements in patient-reported lean tissue and other quality-of-life-adjacent measures at certain doses, alongside a generally tolerable safety profile at the doses tested, but the study was not designed or powered to detect changes in mortality, major disease incidence, or validated biological aging clocks as its primary outcome ^[8]. Epigenetic clock testing (DNA methylation age panels) has become popular among longevity clinics using rapamycin, and some patient testimonials cite favorable changes on these tests. There is no peer-reviewed, controlled trial establishing that rapamycin reliably slows a validated epigenetic clock in humans, and epigenetic clocks themselves are still an active, debated area of validation research, not a settled proxy for lifespan. Anyone evaluating before-and-after claims from clinics or individual users should treat single-person biomarker snapshots as anecdotes, not evidence, given the total absence of controlled human outcome data.

How does rapamycin compare to other longevity interventions people are trying?

Rapamycin has more animal lifespan-extension replication behind it than almost any other compound being sold in the longevity space today, but that comparison mostly highlights how weak the evidence bar is across the whole category, not how strong rapamycin's human case is. | Intervention | Best evidence type | Human lifespan trial completed? |

Who should not take rapamycin off-label, and what monitoring is standard?

People with active or recent serious infections, significant pre-existing kidney disease, uncontrolled diabetes or severe dyslipidemia, poor wound healing, a history of certain cancers, or women who are pregnant or breastfeeding are generally considered poor candidates for off-label rapamycin, based on the known risk profile from transplant medicine and standard prescribing caution . A full list of specific contraindications should be reviewed with a prescriber, since interactions with other medications (particularly strong CYP3A4 inhibitors or inducers) can meaningfully change drug exposure . Standard monitoring for off-label users typically includes a lipid panel, fasting glucose or HbA1c, complete blood count, and kidney and liver function tests before starting and periodically during use, since these are the systems most affected by mTOR inhibition based on the transplant literature . Some prescribers also check sirolimus trough blood levels periodically, particularly if dose changes or interacting medications are introduced. Details on what a full blood work schedule should look like are worth reviewing before the first prescription, not after side effects show up. This is also where a provider-reviewed process matters more than a la carte purchasing. Sirolimus Rx connects patients with licensed prescribers who review history and labs before writing a prescription, and fulfillment runs through a licensed U.S. pharmacy partner rather than an unregulated supplier, which matters given how much dose accuracy and drug purity affect both safety and any hoped-for benefit; separately worth reading is how purity and testing works for compounded and generic sirolimus products before choosing a source.

What would it take to prove rapamycin extends human lifespan?

A definitive answer would require a large, long, randomized, placebo-controlled trial in humans with mortality or major age-related disease incidence as the primary endpoint, something that does not currently exist for rapamycin and would be extremely expensive and slow to run given human lifespans. The closest model for what such a trial would look like is the proposed TAME trial (Targeting Aging with Metformin), designed to enroll thousands of older adults and track time to a composite of major age-related diseases over several years, using metformin rather than rapamycin, and it has faced years of funding challenges rather than proceeding to full enrollment . No equivalent large-scale funded human aging trial exists yet for rapamycin. Shorter-term, more feasible human trials measuring healthspan proxies (frailty measures, validated biological age clocks, infection rates, cardiometabolic markers) over 2 to 5 years could plausibly happen sooner and would meaningfully upgrade the evidence base, even without a mortality endpoint. Until something like that exists and reports results, the field's actual position is: strong mechanistic and animal rationale, encouraging but thin human tolerability and biomarker data, and zero human proof of lifespan extension. That gap is the single most important thing to understand before starting rapamycin for longevity purposes, and it's worth re-reading the mouse data in before-and-after claims with that gap firmly in mind.

Frequently asked questions

Does rapamycin actually extend human lifespan?

Nobody knows yet. There is no completed human trial measuring rapamycin's effect on lifespan. Mouse data from the NIA Interventions Testing Program shows consistent 9-26% lifespan extension across multiple studies ^[1][2][3], but that result has never been replicated in a human outcomes trial, so any human lifespan claim is extrapolation, not proven fact.

Is sirolimus the same drug as rapamycin?

Yes, they're the same molecule. Rapamycin is the compound's original name, discovered in a soil bacterium on Rapa Nui (Easter Island); sirolimus is its generic pharmaceutical name ^[11]. Rapamune is the original FDA-approved brand for transplant use, while Fyarro and Hyftor are newer approved formulations for unrelated specific conditions ^[4][5][12].

What is the NIA Interventions Testing Program and why does it matter?

The Interventions Testing Program is a National Institute on Aging-funded effort testing candidate longevity compounds in genetically diverse mice at three independent labs simultaneously ^[1]. It matters because it's designed to catch results that only work in one lab or one mouse strain; rapamycin is the program's most consistently replicated positive finding for lifespan extension.

What's the difference between how transplant patients and longevity users take rapamycin?

Transplant patients take continuous daily doses targeted to a specific blood trough level to prevent organ rejection ^[10]. Off-label longevity users typically take much lower doses (often 3-10 mg) once weekly, an intermittent schedule based on a pharmacokinetic hypothesis about sparing mTORC2, but this schedule has not been tested in a completed human lifespan or long-term safety trial ^[8][9].

What are the most common side effects of low-dose rapamycin?

Mouth ulcers (stomatitis) are the most commonly reported side effect even at low intermittent doses ^[8][10]. Other documented effects, mostly from higher-dose transplant use, include elevated cholesterol and triglycerides, changes in blood glucose, delayed wound healing, and increased infection risk from immunosuppression ^[10]. Routine blood work helps catch metabolic changes early.

Can rapamycin suppress my immune system at low longevity doses?

It's a real risk, though probably smaller than at transplant doses. Rapamycin's FDA label for transplant use includes clear warnings about increased infection risk and malignancy from immunosuppression ^[10]. Whether low, intermittent, once-weekly longevity dosing meaningfully suppresses immunity long-term hasn't been established in a completed human trial.

Has rapamycin been tested in dogs or other animals besides mice?

Yes. The Dog Aging Project's TRIAD trial is a randomized, placebo-controlled study testing low-dose rapamycin in middle-aged pet dogs, looking at healthspan and cardiac function markers ^[6]. It's an active area of research but hasn't reported a completed lifespan endpoint, and results in dogs still wouldn't directly prove effects in humans.

Is rapamycin FDA-approved for anti-aging use?

No. Sirolimus is FDA-approved only as an immunosuppressant for organ transplant rejection, plus separate approvals under other brand names (Fyarro, Hyftor) for unrelated rare conditions ^[4][5][12]. Any use for aging, longevity, or lifespan extension is entirely off-label, meaning it's legal for a doctor to prescribe but not backed by the trials that earned FDA approval.

What dose of rapamycin do the mouse lifespan studies actually use?

ITP studies typically administer rapamycin continuously through the diet (encapsulated to survive digestion), not as an intermittent weekly human-style dose. Doses varied across cohorts, with higher doses generally producing larger lifespan gains, up to roughly 23-26% at the highest tested doses in some cohorts ^[2][3]. This continuous protocol is quite different from typical off-label human dosing.

Are there any completed clinical trials on rapamycin for healthy aging in humans?

A few small, short trials exist. Mannick et al. (2014) tested a mTOR inhibitor over six weeks and found improved flu vaccine response in elderly adults ^[7]. The PEARL trial tested low-dose intermittent rapamycin over about 48 weeks with tolerability and biomarker outcomes ^[8]. Neither measured lifespan or major disease incidence, and no large outcomes trial has completed.

How is rapamycin different from everolimus?

Everolimus is a chemically modified rapamycin analog (a "rapalog") with a shorter half-life, used in transplant medicine (Zortress) and oncology (Afinitor). It shares rapamycin's mTOR-inhibition mechanism but isn't chemically identical to sirolimus, and it hasn't been through the same extensive ITP mouse lifespan testing that sirolimus has ^[1].

Should I get blood work done before starting rapamycin off-label?

Yes, this is standard practice among careful prescribers. Baseline lipid panel, fasting glucose or HbA1c, complete blood count, and kidney and liver function tests are typical, since these systems are most affected by mTOR inhibition in the transplant literature ^[10]. Periodic monitoring during use helps catch metabolic or blood count changes before they become problems.

Sources

1. National Institute on Aging, Interventions Testing Program: Multi-site NIA program testing longevity compounds in genetically diverse mice; rapamycin is its most consistently replicated finding
2. Harrison DE, et al., Nature (2009): Rapamycin extended median mouse lifespan 9% in males and 13% in females when started at 600 days of age
3. Miller RA, et al., Aging Cell (2014), NIA ITP data: Higher rapamycin doses in later ITP cohorts extended female mouse lifespan by roughly 23-26%
4. Mannick JB, et al., Science Translational Medicine (2014): mTOR inhibitor improved influenza vaccine response in elderly adults over a six-week trial
5. National Institute on Aging, "Rapamycin and the biology of aging" research summary: mTOR inhibition and autophagy are proposed mechanisms behind rapamycin's lifespan effects
6. NIH National Cancer Institute, Drug Dictionary entry for sirolimus: Sirolimus originates from a compound (rapamycin) isolated from Streptomyces hygroscopicus found on Rapa Nui (Easter Island)
7. FDA, Rapamune approval history: Rapamune is the original FDA-approved oral sirolimus brand for organ transplant rejection
8. Ravussin E, et al., CALERIE trial, Journals of Gerontology (2015)/NIA summary: Two-year randomized human caloric restriction trial showed metabolic and immune biomarker changes without a lifespan endpoint